Eupraxia PharmaceuticalsEPRX
13F holders, Q1 2025 (March 31)11holders +2
4new positions
2sold out
1famous investor
$3.27avg. 13F price*
At the end of Q1 2025, 11 institutions reported holding Eupraxia Pharmaceuticals Inc. (EPRX) in their 13F filings, up 2 from Q4 2024. 4 opened new positions and 2 sold out. The largest holders were Scotia Capital Inc. ($5.1M), Royal Bank of Canada ($1.1M) and TD Waterhouse Canada Inc. ($343K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Eupraxia Pharmaceuticals Inc.
- CUSIP
- 29842P105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $400K |
| Exits | 2 | $65K |
All 13F filers, Q4 2024 → Q1 2025: 366,803 shares bought and 25,480 shares sold, net +341,323 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Scotia Capital Inc. | 0.03% | Add +11.6% | 1,552,679 | $5.1M |
| Royal Bank of Canada | 0.00% | Add +21.1% | 342,828 | $1.1M |
| TD Waterhouse Canada Inc. | 0.00% | New | 104,986 | $343K |
| Bank of Montreal | 0.00% | Reduce -7.9% | 52,250 | $171K |
| UBS Group AG | 0.00% | Add +82.8% | 51,199 | $168K |
| Goldman Sachs Group Inc. | 0.00% | No change | 34,500 | $113K |
| Citadel Advisors | 0.00% | New | 12,054 | $39K |
| Raymond James Financial Inc. | 0.00% | Reduce -4.1% | 11,133 | $37K |
| JPMorgan Chase & Co. | 0.00% | New | 2,700 | $9K |
| Bank of America Corp. | 0.00% | New | 2,500 | $8K |
| National Bank of Canada | 0.00% | Add +1676.7% | 764 | $2K |
"% of holder's portfolio" is EPRX's weight in each manager's 13F, not the share of Eupraxia Pharmaceuticals Inc. the manager owns.